Dear Colleagues,

Welcome to the Winter/Spring edition of the Stanford Digestive Health newsletter. This is my favorite time of the year when the flowers are blooming amidst snowcapped mountains and where the new year's promise meets the everyday routine.

In this latest addition, we highlight advancements in clinical trials, multidisciplinary approaches to complex medical conditions and introduce the future of our field. This issue focuses on cutting-edge research in gastroenterology and hepatology, featuring active clinical trials enrolling patients for primary biliary cholangitis (PBC), metabolic steatohepatitis (MASH), and eosinophilic esophagitis (EoE). These trials represent significant strides in our understanding and treatment of these challenging diseases, offering potential new therapeutic avenues for affected individuals.

Beyond these critical clinical trials, we are excited to introduce two new programs multidisciplinary programs dedicated to neuroimmune axis disorders and transplant oncology. The neuroimmune axis disorders program fosters collaborative research and clinical care, exploring the intricate connections between the gastrointestinal, nervous and immune systems. The transplant oncology program brings multidisciplinary innovation to treat cancers involving the liver. This collaborative model aims to optimize patient outcomes by integrating the latest advancements in surgical oncology, interventional radiology, medical oncology and liver transplantation.

Central to our mission is the training of the next generation of gastroenterologists. In this edition, you will meet the phenomenal class of 2027. Our commitment to advancing medical knowledge and patient care drives us to share these developments with you. We hope this newsletter provides a peek into the exciting developments within Stanford Gastroenterology & Hepatology.

Enjoy the exciting content, and, as always, we look forward to hearing back from you.